• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Intravitreal melphalan may control retinoblastoma seeds

bys25qthea
January 10, 2014
in Chronic Disease, Oncology, Ophthalmology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Monthly intravitreal injections of 20 to 30 µg/0.1 mL melphalan were administered to 11 consecutive eyes across 11 patients. 

2. Administration of a mean of 5 intravitreal injections per eye led to complete regression of vitreous seeds; no recurrence was noted over an average follow-up time of 9 months. 

Evidence Rating: 2 (Good) 

Study Rundown: In cases of retinoblastoma, vitreous seeds of cancerous cells provide a daunting therapeutic challenge. Due to their location and distinct from the blood supply, vitreous seeds are often minimally responsive to intravenous or intra-arterial chemotherapy. This study investigated the efficacy and complications of intravitreal injections of melphalan for control of vitreous retinoblastoma seeds. Though dosing was typically continued over 6 injections, after an average of 2 injections, complete resolution of the vitreous seeds was observed with no recurrence noted within a 9-month follow-up period. This study provides preliminary evidence that intravitreal melphalan may resolve vitreous retinoblastoma seeds with only minimal complications. More studies are required to determine the stability of these results, investigate potential long-term complications, and to determine the feasibility of this treatment for subretinal seeds and solid intraretinal tumors.

Click to read the study in JAMA Ophthalmology

Relevant Reading: Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma

RELATED REPORTS

#VisualAbstract: Hereditary retinoblastoma survivors are at an increased risk for melanoma and non-melanoma skin cancers

2 Minute Medicine Rewind October 16, 2017

Patient Basics: Retinoblastoma

In-Depth [retrospective cohort]: This retrospective study gauged the efficacy and complications of intravitreal melphalan injections in 11 consecutive eyes of 11 patients with retinoblastoma previously treated for their primary tumor with intravenous (5 patients) or intra-arterial (6 patients) chemotherapy. At an average age of 37 months, persistent or recurrent viable vitreous seeds were observed in all patients after primary treatment. All patients received intravitreal injections of 20 to 30 µg/0.1 mL melphalan at monthly intervals. In order to minimize the risk of extraocular seeding of cancerous tissue, melphalan injections were placed near, not directly at, the site of vitreous seeding, and triple-freeze cryotherapy was applied to the site of injection.

The study proposed that all patients should receive 6 injections, however fewer doses were provided if complete vitreous seed control was achieved or at the family’s request. A mean of 5 injections per eye were administered. Complete resolution of the vitreous seeds was observed in all 11 eyes. A mean of 2 injections were required to observe the complete response, though more injections were often administered after this point. After a mean follow-up time of 9 months, none of the 11 eyes showed signs of recurrence. There was no aspiration of vitreous fluid or tumor dissemination observed during this study. No other major complications such as vitreous infection, hemorrhage, or retinal detachment were observed. However, minor complications included 2 eyes presenting with minor focal pigment epithelial mottling and 2 eyes with extra-axial posterior lens opacity. There were no signs of retinal edema or vasculopathy.

By Michael Milligan and James Jiang

More from this author: Intranasal oxytocin may improve sociocommunicational deficits in autism

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: retinoblastoma
Previous Post

Artificial surfactant linked to significant improvement of RDS [Pediatrics Classics Series]

Next Post

Hands-on ophthalmic training for medical students may improve knowledge base

RelatedReports

#VisualAbstract: Hereditary retinoblastoma survivors are at an increased risk for melanoma and non-melanoma skin cancers
StudyGraphics

#VisualAbstract: Hereditary retinoblastoma survivors are at an increased risk for melanoma and non-melanoma skin cancers

January 4, 2022
Concomitant HPV vaccine administration equivalent to staggered schedule
Weekly Rewinds

2 Minute Medicine Rewind October 16, 2017

October 25, 2017
Health A to Z

Patient Basics: Retinoblastoma

November 30, 2014
Retinopathy of prematurity associated with nonvisual impairment in childhood
Chronic Disease

Functional decline in children with retinoblastoma greater than expected

July 19, 2014
Next Post
Blindness and visual impairment decreasing worldwide

Hands-on ophthalmic training for medical students may improve knowledge base

Certain cancer therapy innovations not associated with decreasing mortality

Preoperative MRI staging shows no risk reduction of breast cancer recurrence

Isolated thrombocytopenia uncommon in children treated for ALL [Pediatrics Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abuse during childhood and young adulthood is linked to welfare receipt
  • Faecal haemoglobin concentrations associated with mortality and cause of death in colorectal cancer screening
  • The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options